Filing Details

Accession Number:
0001839516-22-000004
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-01 20:09:28
Reporting Period:
2022-11-29
Accepted Time:
2022-12-01 20:09:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1819790 Tarsus Pharmaceuticals Inc. TARS Biological Products, (No Disgnostic Substances) (2836) 814717861
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1839516 C. Dianne Whitfield C/O Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road, Suite 160
Irvine CA 92618
Chief Human Resources Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-11-29 10,251 $0.00 12,224 No 4 M Direct
Common Stock Disposition 2022-11-30 1,182 $16.50 11,042 No 4 S Direct
Common Stock Disposition 2022-12-01 1,165 $16.75 9,877 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2022-11-29 10,251 $0.00 10,251 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
23,920 No 4 M Direct
Footnotes
  1. The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2022.
  2. Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
  3. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  4. RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service.